In the conventional process of developing Antibody-Drug Conjugates (ADCs), a target molecule (antigen) specifically expressed in the tumor must first be selected, followed by the preparation of a monoclonal antibody against the target. If the target is included in the library, there is no need to prepare a new monoclonal antibody, humanize it, or modify amino acid residues for linker attachment. Even if a target antigen is not included in the library, the AMDC platform can utilize computational modeling to rapidly generate a specific antibody-like molecule. For the payloads to be delivered, libraries have been constructed in which Psyche is conjugated to DNA alkylating agents, photosensitizers, and radioisotope-containing compounds, among others. By integrating the Cupid and Psyche libraries, the AMDC platform aims to provide research reagents, diagnostic reagents, and therapeutic agents.